Introduction
Malaria is an anthroponotic protozoan disease with a transmissible mechanism of transmission. It is characterized by a cyclic course: a change of febrile attacks and interictal states, splenohepatomegaly, anemia. Diagnosis is made on the basis of clinical data, epidemiological data and laboratory results. The characteristic clinical symptoms are typical febrile paroxysms with tremendous chills, a rapid increase in body temperature to high numbers, followed by profuse sweat.
Currently, there are certain difficulties in the treatment and therapy of malaria. It is very expensive and does not always prove its effectiveness. Moreover, outbreaks of drug-resistant malaria are currently being observed in some countries in Africa.
Vaccine
Moreover, outbreaks of drug-resistant malaria are currently being observed in some countries in Africa. Regular monitoring of drug efficacy is required to develop treatment strategies for malaria-endemic countries and to detect and control drug resistance in a timely manner.
In developing countries, about 500 million cases of infection are recorded annually. About 435 thousand people, mostly children, die from malaria every year. Thus, the development of a drug that can defeat the epidemic is urgent for scientists. Pyrazole-urea compounds may be effective antimalarials because they competitively inhibit a key protein-protein interaction between MTIP and MyoA (Kortagere et al., 2010). Vaccines would be useful in the fight against malaria, but they are even worse than drugs. The main problem is the life cycle of plasmodia(Ashley & Phyo, 2018). For each stage of the parasite, the immune system has to pick up a new weapon. In addition, Plasmodium has other tricks to bypass host defenses, and is much more complex than the viruses that most effective vaccines work against.
References
Ashley, E. A., & Phyo, A. P. (2018). Drugs in development for malaria. Drugs, 78(9), 861-879.
Kortagere, S., Welsh, W. J., Morrisey, J. M., Daly, T., Ejigiri, I., Sinnis, P., Vaidya, A.B. & Bergman, L. W. (2010). Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum. Journal of Chemical Information and Modeling, 50(5), 840-849.